159 related articles for article (PubMed ID: 37012415)
1. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.
Baranwal A; Chhetri R; Yeung D; Clark M; Shah S; Litzow MR; Hogan WJ; Mangaonkar A; Alkhateeb HB; Singhal D; Cibich A; Bardy P; Kok CH; Hiwase DK; Shah MV
Bone Marrow Transplant; 2023 Jul; 58(7):769-776. PubMed ID: 37012415
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
Nakamura S; Yokoyama K; Shimizu E; Yusa N; Kondoh K; Ogawa M; Takei T; Kobayashi A; Ito M; Isobe M; Konuma T; Kato S; Kasajima R; Wada Y; Nagamura-Inoue T; Yamaguchi R; Takahashi S; Imoto S; Miyano S; Tojo A
Blood; 2019 Jun; 133(25):2682-2695. PubMed ID: 30936070
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
Shah N; Rakszawski K; Nickolich M; Ehmann C; Wirk B; Naik S; Rybka W; Zheng H; Mierski J; Silar B; Mackey G; Greiner R; Brown V; Claxton D; Mineishi S; Minagawa K
Ann Hematol; 2021 Oct; 100(10):2585-2592. PubMed ID: 34322774
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
5. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
7. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
Baranwal A; Gurney M; Basmaci R; Katamesh B; He R; Viswanatha DS; Greipp P; Foran J; Badar T; Murthy H; Yi CA; Palmer J; Mangaonkar AA; Patnaik MM; Litzow MR; Hogan WJ; Begna K; Gangat N; Tefferi A; Al-Kali A; Shah MV; Alkhateeb HB
Haematologica; 2024 Feb; ():. PubMed ID: 38299584
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
[TBL] [Abstract][Full Text] [Related]
11. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
Juliusson G; Karlsson K; Lazarevic VLj; Wahlin A; Brune M; Antunovic P; Derolf A; Hägglund H; Karbach H; Lehmann S; Möllgård L; Stockelberg D; Hallböök H; Höglund M;
Cancer; 2011 Sep; 117(18):4238-46. PubMed ID: 21387283
[TBL] [Abstract][Full Text] [Related]
13. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.
van Gelder M; de Wreede LC; Schetelig J; van Biezen A; Volin L; Maertens J; Robin M; Petersen E; de Witte T; Kröger N;
Leukemia; 2013 Apr; 27(4):879-88. PubMed ID: 23164802
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma.
Vasudevan Nampoothiri R; Pasic I; Law AD; Lam W; Chen C; Michelis FV; Kim DDH; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2022 May; 108(5):430-436. PubMed ID: 35100661
[TBL] [Abstract][Full Text] [Related]
15. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
16. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Nagler A; Labopin M; Shimoni A; Niederwieser D; Mufti GJ; Zander AR; Arnold R; Greinix H; Cornelissen JJ; Jackson GH; Craddock C; Bunjes DW; Ganser A; Russell NH; Kyrcz-Krzemien S; Rocha V; Mohty M
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1422-9. PubMed ID: 22446014
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality.
Meijer E; Cornelissen JJ
Semin Oncol; 2008 Aug; 35(4):449-57. PubMed ID: 18692695
[TBL] [Abstract][Full Text] [Related]
18. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
[No Abstract] [Full Text] [Related]
19. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
20.
Shallis RM; Podoltsev NA; Gowda L; Zeidan AM; Gore SD
Expert Rev Hematol; 2020 May; 13(5):447-460. PubMed ID: 32182435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
